trial

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

NCTId NCT01192880
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 625 (actual)
Sponsored by Hoffmann-La Roche
Primary completion 2014-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
625 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-11
Primary completion
2014-07
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
AntipsychoticsBitopertin

Sponsors

Hoffmann-La RocheLead Sponsor

Sites

103 total
Costa Mesa, United StatesEscondido, United StatesGranada Hills, United StatesLa Jolla, United StatesOceanside, United StatesSan Diego, United StatesTorrance, United StatesLauderhill, United StatesMiami, United StatesOrange City, United StatesPlantation, United StatesAtlanta, United States

Linked catalysts

1
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persi — primary completion2014-07

Facts & assertions

4 sourced
Enrollment
625
Phase
PHASE3
Primary Completion Date
2014-07
Status
COMPLETED
relationships
The graph out of here
drug
Antipsychotics
drug
Bitopertin
drug
lead_sponsor
Hoffmann-La Roche
company
indication
Schizophrenia
indication
Schizophrenia
indication